Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1989 Oct;27(10):2305–2308. doi: 10.1128/jcm.27.10.2305-2308.1989

Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers.

S Maoleekoonpairoj 1, A Mittelman 1, S Savona 1, T Ahmed 1, C Puccio 1, E Gafney 1, A Skelos 1, P Arnold 1, N Coombe 1, P Baskind 1, et al.
PMCID: PMC267014  PMID: 2584381

Abstract

A survey of patients with advanced cancer treated by biologic response modifiers (BRMs), including (i) recombinant interleukin-2 and lymphokine-activated killer cells, (ii) recombinant interleukin-2 and alpha interferon, and (iii) tumor necrosis factor, was done. A total of 52 patients were reviewed. A total of 73 courses of BRMs were administered. Prior to the initiation of therapy, all patients were infection free and not receiving antibiotics. Twelve patients developed bacteremia during treatment with these BRMs. Five of these 12 patients had catheter-related bacteremia. Six patients had bacteremic infections without an obvious source, and one patient had a urinary tract infection with bacteremia. Staphylococcus epidermidis accounted for six of the isolates. Other organisms were Staphylococcus aureus, group B streptococci, viridans group streptococci, and gram-negative bacilli. This was an unexpectedly high incidence of bacterial infections in patients treated with BRMs. These BRMs have been previously shown to be efficacious against infections (by bacteria and other intracellular organisms) in experimental animals. In this study BRMs did not influence host defense mechanisms or offer protection against bacterial infections.

Full text

PDF
2305

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campbell P. A., Canono B. P., Cook J. L. Mouse macrophages stimulated by recombinant gamma interferon to kill tumor cells are not bactericidal for the facultative intracellular bacterium Listeria monocytogenes. Infect Immun. 1988 May;56(5):1371–1375. doi: 10.1128/iai.56.5.1371-1375.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dinarello C. A., Mier J. W. Lymphokines. N Engl J Med. 1987 Oct 8;317(15):940–945. doi: 10.1056/NEJM198710083171506. [DOI] [PubMed] [Google Scholar]
  3. Fauci A. S., Rosenberg S. A., Sherwin S. A., Dinarello C. A., Longo D. L., Lane H. C. NIH conference. Immunomodulators in clinical medicine. Ann Intern Med. 1987 Mar;106(3):421–433. doi: 10.7326/0003-4819-106-3-421. [DOI] [PubMed] [Google Scholar]
  4. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Iizawa Y., Nishi T., Kondo M., Tsuchiya K., Imada A. Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice. Infect Immun. 1988 Jan;56(1):45–50. doi: 10.1128/iai.56.1.45-50.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kelly C. S., Ligas J. R., Smith C. A., Madden G. M., Ross K. A., Becker D. R. Sepsis due to triple lumen central venous catheters. Surg Gynecol Obstet. 1986 Jul;163(1):14–16. [PubMed] [Google Scholar]
  7. Lotze M. T., Chang A. E., Seipp C. A., Simpson C., Vetto J. T., Rosenberg S. A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA. 1986 Dec 12;256(22):3117–3124. [PubMed] [Google Scholar]
  8. Murphy P. M., Lane H. C., Gallin J. I., Fauci A. S. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma. Ann Intern Med. 1988 Jan;108(1):36–41. doi: 10.7326/0003-4819-108-1-36. [DOI] [PubMed] [Google Scholar]
  9. Murray H. W. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med. 1988 Apr;108(4):595–608. doi: 10.7326/0003-4819-108-4-595. [DOI] [PubMed] [Google Scholar]
  10. Nathan C. F., Murray H. W., Wiebe M. E., Rubin B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983 Sep 1;158(3):670–689. doi: 10.1084/jem.158.3.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pemberton L. B., Lyman B., Lander V., Covinsky J. Sepsis from triple- vs single-lumen catheters during total parenteral nutrition in surgical or critically ill patients. Arch Surg. 1986 May;121(5):591–594. doi: 10.1001/archsurg.1986.01400050109014. [DOI] [PubMed] [Google Scholar]
  12. Rosenberg S. A., Lotze M. T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol. 1986;4:681–709. doi: 10.1146/annurev.iy.04.040186.003341. [DOI] [PubMed] [Google Scholar]
  13. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  14. Shalaby M. R., Aggarwal B. B., Rinderknecht E., Svedersky L. P., Finkle B. S., Palladino M. A., Jr Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol. 1985 Sep;135(3):2069–2073. [PubMed] [Google Scholar]
  15. Sherman M. L., Spriggs D. R., Arthur K. A., Imamura K., Frei E., 3rd, Kufe D. W. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988 Feb;6(2):344–350. doi: 10.1200/JCO.1988.6.2.344. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES